Association of multiple myeloma and inflammatory bowel diseases.
Liu
Hong
H
Moreb
Jan S
JS
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000139:chemically induced*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000069285:Infliximab; D000077561:Daclizumab
Mod Pathol. 2004 Apr;17(4):389-94
14976525
Dig Dis Sci. 2007 Sep;52(9):2022-8
17420948